

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: ALLEN

Serial No.: 09/904,180

Filed: July 11, 2001



Art Unit: 1636

Examiner: Pappu, Sita S.

Atty. Dkt.: R-477

For: TRANSGENIC MICE CONTAINING STEFIN HOMOLOG PROTEASE INHIBITOR GENE DISRUPTIONS

RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

MAY 10 2002

Madam:

TECH CENTER 1600/2900

In response to the Office Action mailed April 8, 2002, concerning the Examiner's restriction requirement, Applicant hereby provisionally elects, with traverse, Invention Group I (Claims 1-15 and 17-26), drawn to a targeting construct, a method of producing the targeting construct, a cell comprising a disruption in a stefin homolog gene, a non-human transgenic animal comprising a disruption in a stefin homolog gene, a method of producing a transgenic mouse, a method of identifying an agent that modulates the expression and/or function of a stefin homolog gene, a transgenic mouse with increased activity, a transgenic mouse with increased activity and a decreased propensity for despair, and a method of identifying an agent that modulates the expression and function of a phenotype associated with a disruption in a stefin homolog gene.

In the Office Action, it is asserted that claims 1-27 are drawn to three distinct subjects, grouped as:

Invention I, claims 1-15 and 17-26 (drawn to a targeting construct, a method of producing the targeting construct, a cell comprising a disruption in a stefin homolog gene, a non-human transgenic animal comprising a disruption in a stefin homolog gene, a method of producing a transgenic mouse, a method of identifying an agent that modulates the expression and/or function of a stefin homolog gene, a transgenic mouse with increased activity, a transgenic mouse with